<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098616</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #1285</org_study_id>
    <secondary_id>AI443-128</secondary_id>
    <nct_id>NCT02098616</nct_id>
  </id_info>
  <brief_title>Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus</brief_title>
  <acronym>RHACE 1</acronym>
  <official_title>RHACE 1: Rapid HepAtitis C Elimination Trial - A Pilot Evaluation of Twice Daily Fixed Dose Combination Asunaprevir +Daclatasvir + BMS-791325 ± Weight Based Ribavirin in Treatment-Naïve, Non-cirrhotic Patients With Chronic Genotype 1a Hepatitis-C for Eight, Six or Four Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Morgan, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Long Beach Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with
      Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is
      feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>Post treatment week 12</time_frame>
    <description>Proportion of treated subjects in each enrolled arm with sustained virologic response (SVR)12. SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) target detected or target not detected (TD/TND) at post treatment Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to end of treatment (+7 days)</time_frame>
    <description>On treatment safety, as measured by frequency of serious adverse events (SAEs) and adverse events (AEs), discontinuations due to AEs, and rates and grades of select laboratory abnormalities including liver function tests and hematology laboratory abnormalities in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic response</measure>
    <time_frame>2, 4 and 24 weeks post-treatment</time_frame>
    <description>Proportion of treated subjects in each arm with SVR2, SVR4 and SVR 24, defined as HCV RNA &lt; lower limit of quantification (LLOQ) target detected or target not detected (TD/TND) at post treatment Weeks, 2, 4, and 24 respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post treatment virologic response</measure>
    <time_frame>post treatment Weeks 2 (SVR2), 4 (SVR4), and 24 (SVR24)</time_frame>
    <description>To assess the proportion of subjects who achieve sustained virologic response (SVR) 2, SVR4 and SVR24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On treatment virologic response</measure>
    <time_frame>On-treatment Day 2 and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>To assess antiviral activity, as measured by the proportion of subjects who achieve HCV RNA &lt;lower limit of detection (LLOD) and/or &lt; lower limit of quantification (LLOQ) at each on treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic failure</measure>
    <time_frame>On-treatment Day 2 and Weeks 1, 2, 4, 6, 8 and 12 and Post Treatment Weeks 2, 4, 12 and 24</time_frame>
    <description>To assess the proportion of subjects with virologic failure (including on treatment virologic breakthrough and relapse) and evaluate the emergence of viral resistant mutations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 2 positive predictive value</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <description>To assess the predictive value of Day 2 virologic response on sustained virologic response (SVR) 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon lambda genotype and virologic response</measure>
    <time_frame>On-treatment Day 2 and Weeks 1, 2, 4, 6, 8 and 12 and Post Treatment Weeks 2, 4, 12 and 24</time_frame>
    <description>To compare the virologic response of subjects by genotype for interferon (IFN) lambda variants [' IL28B' and IFNL4-ΔG]</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV/ASV/BMS-791325</intervention_name>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Fixed Dose Combination (FDC) of Daclatasvir/Asunaprevir/BMS-791325</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV/ASV/BMS-791325 + RBV</intervention_name>
    <description>Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects chronically infected with HCV genotype 1a

          -  HCV RNA ≥ 10,000 IU/mL at screening

          -  Treatment-naïve subjects with no previous exposure to an interferon formulation (ie,
             IFNα, pegIFNα), ribavirin (RBV), or HCV direct acting antiviral (DAA; protease,
             polymerase inhibitor, etc.)

        Exclusion Criteria:

          -  Evidence of cirrhosis

          -  Liver or any other organ transplant

          -  Current or known history of cancer within 5 years prior to enrollment

          -  Documented or suspected hepatocellular carcinoma (HCC)

          -  Not eligible for sofosbuvir + pegylated interferon + ribavirin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy R. Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Long Beach Healthcare System/Southern California Institute for Research and Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Timothy Morgan, MD</investigator_full_name>
    <investigator_title>Chief, Hepatology</investigator_title>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis, Chronic</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Hepatitis, Viral, Human</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Drug Resistance, Viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 4, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

